Novartis touts phase III prostate cancer study results

By AuntMinnie.com staff writers

March 23, 2021 -- Novartis is highlighting results from a phase III study that has investigated the efficacy and safety of Lu-177 PSMA-617, a radioligand therapy for patients with prostate-specific membrane antigen (PSMA)-positive metastatic prostate cancer.

Phase III of the VISION trial found that Lu-177 PSMA-617 improved overall survival and radiographic progression-free survival in patients with PSMA-positive metastatic castration-resistant prostate cancer, according to Novartis.

Radioligand therapy consists of a targeting compound that attaches to tumor markers and a radioactive isotope, both of which inhibit tumor growth, the company said.


Copyright © 2021 AuntMinnie.com
 

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: